Healthcare Outlook

Nonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) in which a person have hepatitis and inflammation of the liver, and can cause liver damage. NASH can lead to complications, such as cirrhosis and liver cancer. Patients with NASH have high chance of mortality due to liver-related causes such as liver failure.

Lifestyle modification, including change in diet and exercise, is the basic therapy recommended for nonalcoholic fatty liver disease. However, in some cases lifestyle modification is difficult to achieve and to sustain, and therefore required other treatments including medicine.

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2279

Currently available drugs for the treatment of NAFLD were historically been given for other indications. For instance, Orlistat, a gut lipase inhibitor, is indicated for decrease in the dietary fats absorption. According to the National Center for Biotechnology Information (NCBI) 2017 study, Orlistat has been approved for treatment of obesity and is available over the counter in the U.S. for weight loss. Orlistat-mediated weight loss is related with reduction in hepatic steatosis.

The global nonalcoholic steatohepatitis treatment market size was valued at US$ 1,119.9 million in 2017 (based on existing approved therapies anti-diabetics, vitamins, dietary supplements, and others) and is expected to witness a CAGR of 42.7% over the forecast period (2018 – 2026).

Rising incidence of nonalcoholic steatohepatitis and strong product pipeline are expected to drive the nonalcoholic steatohepatitis treatment market revenue

Nonalcoholic steatohepatitis has become one of the most common liver-related health problems. The condition has been linked to an unhealthy diet and weight gain, but it can also be observed in non-obese individuals. Increasing prevalence of insulin resistance, and obesity is expected to fuel the nonalcoholic steatohepatitis treatment market during the forecast period.

According to an article published in Lancet, globally, prevalence of overweight and obesity combined has risen by 27.5% for adults between 1980 and 2013. According to the National Health and Nutrition Examination Survey (NHANES) 2014 data, in U.S. the percentage of obesity is higher in women, i.e. 40%, than in men, 35%.

Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/nonalcoholic-steatohepatitis-treatment-market-2279

Nonalcoholic Steatohepatitis Treatment Market - Regional Insights

On the basis of region, the global nonalcoholic steatohepatitis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe nonalcoholic steatohepatitis treatment market is expected to foresee significant growth owing to increasing incidence of obesity and fatty liver.

Nonalcoholic Steatohepatitis Treatment Market - Competitive Landscape

Key players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.

Detailed Segmentation:

Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:

Cenicriviroc

Elafibranor

Ocaliva (Obeticholic Acid)

Selonsertib

Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

To Get Instant Access, Purchase Report Here: https://www.coherentmarketinsights.com/insight/buy-now/2279

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com